Nivolumab Market Forecasts Indicate Robust Growth Driven by Advances in Cancer Immunotherapy and Increased Global Access to Care


Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Nivolumab Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Recent advancements in cancer treatment and the accelerated development of novel cancer therapeutics have marked a significant upswing in the global nivolumab market. As healthcare systems worldwide heighten their focus on efficacious immunotherapies, the demand for nivolumab—a premier immune checkpoint inhibitor—continues to surge.

An extensive analysis of the nivolumab market has culminated in a comprehensive report revealing that the market size, notably bolstered by increased cancer incidence and remarkable clinical success, expanded to $1.47 billion in 2023. Following this trajectory, the market is projected to further grow to $1.69 billion in 2024, flourishing at a compound annual growth rate (CAGR) of 15.1%. The forecast period paints an even more optimistic picture, with expectations of the market reaching $2.81 billion by 2028 at a CAGR of 13.6%.

The report illuminates the pivotal factors propelling market growth, including but not limited to the rapid advancements in personalized medicine, the burgeoning exploration of emerging indications for cancer treatment, the far-reaching accessibility of global cancer care, and the refinement of combination therapies.

Furthermore, the market is witnessing an evolution in trends, with a growing emphasis on biomarker-driven treatments and the advent of neoantigen vaccines. These are complemented by progress in optimizing immunotherapy regimens and acquiring insights from long-term follow-up studies—all of which are anticipated to energize the market.

An in-depth analysis of the factors curating the market landscape has identified an upsurge in the prevalence of cancer, particularly non-small cell lung cancer (NSCLC), as a potent growth stimulant. Yet, the market's expansion is not without challenges; issues such as immune-related adverse events (IR-AEs) pose a substantial constraint and invite increased vigilance and innovation from market players.

In response to the dynamic market needs, industry leaders remain steadfast in their pursuit of groundbreaking drug development. Highlighting this pursuit, recent approvals by regulatory bodies for nivolumab combination therapies mark significant strides towards enhancing the treatment landscape for various cancer subtypes.

The report comprehensively analyzes the nivolumab market, segmenting it based on geographical regions such as North America, Asia-Pacific, Western Europe, and more, as well as by formulations including different intravenous solutions. It comes as no surprise that North America emerged as the largest region in the market in 2023. The scope of the report also extends to an exhaustive examination of key players, types of cancer treated, and market utilization within clinical settings.

  • Find key insights on the rising demand for nivolumab treatments in the newest market report.

  • Discover the growth drivers: Increased incidence of cancer, advancements in personalized medicines, and regulatory approvals shaping the nivolumab market.

  • Understand market dynamics: Learn about emerging trends, opportunities, and potential challenges in the global nivolumab space.


A selection of companies mentioned in this report includes

  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Novartis AG
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Regeneron Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd.
  • Ono Pharmaceutical Co. Ltd.
  • Kyowa Kirin Co. Ltd.
  • Nippon Kayaku Co. Ltd.
  • Luye Pharma AG
  • Genentech Inc.
  • Taiho Pharmaceutical Co. Ltd.
  • SymBio Pharmaceuticals Ltd.
  • Xbrane Biopharma AB
  • NeuClone Therapeutics Inc.


For more information about this report visit https://www.researchandmarkets.com/r/txgmke

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data